Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
Daiichi makes its sting move
The recently unveiled conjugate DS3610a is to start phase 1.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Zymeworks restocks its clinical pipeline
After ZW171's exit, ZW251 enters the clinic.
Merus's next shot is colorectal cancer
Petosemtamab's phase 2 data in this setting should come by the year end.
J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
